APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis

eLife

Volumn 6, Issue , 2017, Pages

  Cooper, Anneli ^a   Ilboudo, Hamidou ^b,c   Alibu, V Pius ^c   Ravel, Sophie ^d   Enyaru, John ^c   Weir, William ^a   Noyes, Harry ^a,c,e   Capewell, Paul ^a   Camara, Mamadou ^c,f   Milet, Jacqueline ^d   Jamonneau, Vincent ^b,c,d   Camara, Oumou ^f   Matovu, Enock ^c   Bucheton, Bruno ^c,d,f   MacLeod, Annette ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Centre International de Recherche Developpement sur lElevage en zone Subhumide Bobo Dioulasso   (Burkina Faso)

^c MAKERERE UNIVERSITY   (Uganda)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f National de Lutte contre la Trypanosomiase Humaine Africaine   (Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN;

AFRICAN TRYPANOSOMIASIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APOL1 GENE; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; GENE; GENE FREQUENCY; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; KIDNEY DISEASE; MICROSCOPY; OUTCOME ASSESSMENT; RISK FACTOR; SEROLOGY; SPATIAL FREQUENCY DISCRIMINATION; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; VEIN PUNCTURE; AFRICA SOUTH OF THE SAHARA; ALLELE; DISEASE RESISTANCE; GENETIC PREDISPOSITION; GENETIC SELECTION; GENETICS; GENOTYPE; IMMUNOLOGY;

AFRICA SOUTH OF THE SAHARA; ALLELES; APOLIPOPROTEIN L1; CASE-CONTROL STUDIES; DISEASE RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY DISEASES; SELECTION, GENETIC; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 85022346173     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.25461     Document Type: Article

References (68)

1. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA, 1000 Genomes Project Consortium. 2012. An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65. doi: 10.1038/nature11632, PMID: 23128226
2. Allison AC. 1954. Protection afforded by sickle-cell trait against subtertian malareal infection. BMJ 1:290–294. doi: 10.1136/bmj.1.4857.290, PMID: 13115700
3. Alsford S, Currier RB, Guerra-Assunção JA, Clark TG, Horn D. 2014. Cathepsin-L can resist lysis by human serum in Trypanosoma brucei brucei. PLoS Pathogens 10:e1004130. doi: 10.1371/journal.ppat.1004130, PMID: 24 830321
4. Balmer O, Beadell JS, Gibson W, Caccone A. 2011. Phylogeography and taxonomy of Trypanosoma brucei. PLoS Neglected Tropical Diseases 5:e961. doi: 10.1371/journal.pntd.0000961, PMID: 21347445
5. Balyeidhusa AS, Kironde FA, Enyaru JC. 2012. Apparent lack of a domestic animal reservoir in gambiense sleeping sickness in northwest uganda. Veterinary Parasitology 187:157–167. doi: 10.1016/j.vetpar.2011.12. 005, PMID: 22245071
6. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K. 2011. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the ethiopian population. American Journal of Nephrology 34:452–459. doi: 10.1159/000332378, PMID: 21968148
7. Bucheton B, MacLeod A, Jamonneau V. 2011. Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunology 33:438–447. doi: 10.1111/j.1365-3024.2011. 01287.x, PMID: 21385185
8. Camara M, Kaba D, KagbaDouno M, Sanon JR, Ouendeno FF, Solano P. 2005. Human African Trypanosomiasis in the Mangrove Forest in Guinea: Epidemiological and Clinical Features in Two Adjacent Outbreak Areas. Revue Du Corps De Santé Colonial: Médecine Tropicale. 65 155–161.
9. Capewell P, Clucas C, DeJesus E, Kieft R, Hajduk S, Veitch N, Steketee PC, Cooper A, Weir W, MacLeod A. 2013. The TgsGP gene is essential for resistance to human serum in Trypanosoma brucei gambiense. PLoS Pathogens 9:e1003686. doi: 10.1371/journal.ppat.1003686, PMID: 24098129
10. Cooper A, Tait A, Sweeney L, Tweedie A, Morrison L, Turner CM, MacLeod A. 2008. Genetic analysis of the human infective trypanosome Trypanosoma brucei gambiense: chromosomal segregation, crossing over, and the construction of a genetic map. Genome Biology 9:R103. doi: 10.1186/gb-2008-9-6-r103, PMID: 18570680
11. De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R. 1989. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Molecular and Biochemical Parasitology 36:169–176. doi: 10.1016/0166-6851(89)90189-8, PMID: 2528066
12. De Greef C, Hamers R. 1994. The serum resistance-associated (SRA) gene of Trypanosoma brucei rhodesiense encodes a variant surface glycoprotein-like protein. Molecular and Biochemical Parasitology 68:277–284. doi: 10.1016/0166-6851(94)90172-4, PMID: 7739673
13. DeJesus E, Kieft R, Albright B, Stephens NA, Hajduk SL. 2013. A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding. PLoS Pathogens 9: e1003317. doi: 10.1371/journal.ppat.1003317, PMID: 23637606
14. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, et al. 2014. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis & Rheumatology 66:390–396. doi: 10.1002/art.38220, PMID: 24504811
15. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. 2011. Population-based risk assessment of APOL1 on renal disease. Journal of the American Society of Nephrology 22:2098–2105. doi: 10.1681/ASN.2011050519, PMID: 21997396
16. Fèvre EM, Coleman PG, Welburn SC, Maudlin I. 2004. Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda. Emerging Infectious Diseases 10:567–573. doi: 10.3201/eid1004.020626, PMID: 15200843
17. Garcia A, Jamonneau V, Magnus E, Laveissière C, Lejon V, N’Guessan P, N’Dri L, Van Meirvenne N, Büscher P. 2000. Follow-up of card agglutination trypanosomiasis test (CATT) positive but apparently aparasitaemic individuals in Côte D’ivoire: evidence for a complex and heterogeneous population. Tropical Medicine and International Health 5:786–793. doi: 10.1046/j.1365-3156.2000.00623.x, PMID: 11123826
18. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. 2010. Association of trypanolytic ApoL1 variants with kidney disease in african Americans. Science 329:841–845. doi: 10.1126/science.1193032, PMID: 20647424
19. Gibson W, Backhouse T, Griffiths A. 2002. The human serum resistance associated gene is ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout East Africa. Infection, Genetics and Evolution 1:207– 214. doi: 10.1016/S1567-1348(02)00028-X, PMID: 12798017
20. Global Burden of Disease Study 2013 Collaborators. 2015. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800. doi: 10.1016/S0140-6736(15)60692-4, PMID: 26063472
21. Godfrey DG, Baker RD, Rickman LR, Mehlitz D. 1990. The distribution, relationships and identification of enzymic variants within the subgenus trypanozoon. Advances in Parasitology 29:1–74. PMID: 2181826
22. H3Africa Consortium. 2013. H3Africa Guidelines for Informed Consent. http://h3africa.org/images/PDF/H3A%20WG%20Guidelines%20Informed%20Consent_FINAL_01082013.pdf
23. Harper K, Armelagos G. 2010. The changing disease-scape in the third epidemiological transition. International Journal of Environmental Research and Public Health 7:675–697. doi: 10.3390/ijerph7020675, PMID: 20616997
24. Hide G. 1999. History of sleeping sickness in East Africa. Clinical Microbiology Reviews 12:112–125. PMID: 9880477
25. Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, Léno M, Ouendeno F, Courtin F, Sakande H, Sanon R, Kaboré J, Coulibaly B, N’Dri L, Diarra A, N’Goran E, Bucheton B. 2011. Diversity of response to Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness. Microbes and Infection 13:943–952. doi: 10.1016/j.micinf.2011.05.007, PMID: 21658462
26. Ilboudo H, Berthier D, Camara M, Camara O, Kabore J, Leno M, Keletigui S, Chantal I, Jamonneau V, Belem AMG, Cuny G, Bucheton B. 2012. APOL1 expression is induced by Trypanosoma brucei gambiense infection but is not associated with differential susceptibility to sleeping sickness. Infection, Genetics and Evolution 12: 1519–1523. doi: 10.1016/j.meegid.2012.05.010
27. Ilboudo H, Bras-Gonçalves R, Camara M, Flori L, Camara O, Sakande H, Leno M, Petitdidier E, Jamonneau V, Bucheton B. 2014. Unravelling human trypanotolerance: il8 is associated with infection control whereas IL10 and tnfα are associated with subsequent disease development. PLoS Pathogens 10:e1004469. doi: 10.1371/journal.ppat.1004469, PMID: 25375156
28. Jamonneau V, Bucheton B, Kaboré J, Ilboudo H, Camara O, Courtin F, Solano P, Kaba D, Kambire R, Lingue K, Camara M, Baelmans R, Lejon V, Büscher P. 2010. Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa. PLoS Neglected Tropical Diseases 4:e917. doi: 10.1371/journal.pntd.0000917, PMID: 21200417
29. Jamonneau V, Ilboudo H, Kaboré J, Kaba D, Koffi M, Solano P, Garcia A, Courtin D, Laveissière C, Lingue K, Büscher P, Bucheton B. 2012. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Neglected Tropical Diseases 6:e1691. doi: 10.1371/journal.pntd.0001691, PMID: 22720107
30. Kaboré J, Koffi M, Bucheton B, MacLeod A, Duffy C, Ilboudo H, Camara M, De Meeṷs T, Belem AM, Jamonneau V. 2011. First evidence that parasite infecting apparent aparasitemic serological suspects in human african trypanosomiasis are Trypanosoma brucei gambiense and are similar to those found in patients. Infection, Genetics and Evolution 11:1250–1255. doi: 10.1016/j.meegid.2011.04.014, PMID: 21530681
31. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S. 2015. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. Journal of the American Society of Nephrology 26:2882–2890. doi: 10.1681/ASN.2014050469, PMID: 25788523
32. Kennedy PG. 2013. Clinical features, diagnosis, and treatment of human african trypanosomiasis (sleeping sickness). The Lancet Neurology 12:186–194. doi: 10.1016/S1474-4422(12)70296-X, PMID: 23260189
33. Kieft R, Capewell P, Turner CM, Veitch NJ, MacLeod A, Hajduk S. 2010. Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor. PNAS 107:16137–16141. doi: 10.1073/pnas.1007074107, PMID: 20805508
34. Ko WY, Rajan P, Gomez F, Scheinfeldt L, An P, Winkler CA, Froment A, Nyambo TB, Omar SA, Wambebe C, Ranciaro A, Hirbo JB, Tishkoff SA. 2013. Identifying darwinian selection acting on different human APOL1 variants among diverse african populations. American Journal of Human Genetics 93:54–66. doi: 10.1016/j. ajhg.2013.05.014, PMID: 23768513
35. Koffi M, Solano P, Denizot M, Courtin D, Garcia A, Lejon V, Büscher P, Cuny G, Jamonneau V. 2006. Aparasitemic serological suspects in Trypanosoma brucei gambiense human african trypanosomiasis: a potential human reservoir of parasites? Acta Tropica 98:183–188. doi: 10.1016/j.actatropica.2006.04.001, PMID: 16723098
36. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, et al. 2011. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. Journal of the American Society of Nephrology 22:2129–2137. doi: 10.1681/ASN.2011040388, PMID: 219973 94
37. Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K. 2016. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrology Dialysis Transplantation 31:349–358. doi: 10.1093/ndt/gfu391, PMID: 25561578
38. Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, Andris F, Lins L, Pays E. 2009. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathogens 5:e1000685. doi: 10.1371/journal.ppat.1000685, PMID: 19997494
39. Limou S, Nelson GW, Lecordier L, An P, O’hUigin CS, David VA, Binns-Roemer EA, Guiblet WM, Oleksyk TK, Pays E, Kopp JB, Winkler CA. 2015. Sequencing rare and common APOL1 coding variants to determine kidney disease risk. Kidney International 88:754–763. doi: 10.1038/ki.2015.151, PMID: 25993319
40. MacLeod A, Welburn S, Maudlin I, Turner CM, Tait A. 2001. Evidence for multiple origins of human infectivity in Trypanosoma brucei revealed by minisatellite variant repeat mapping. Journal of Molecular Evolution 52:290– 301. doi: 10.1007/s002390010157, PMID: 11428466
41. McClellan W, Tuttle E, Issa A. 1988. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. American Journal of Kidney Diseases 12:285–290. doi: 10.1016/S0272-6386(88)80221-X, PMID: 3263042
42. Molina-Portela MP, Lugli EB, Recio-Pinto E, Raper J. 2005. Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes. Molecular and Biochemical Parasitology 144:218–226. doi: 10.1016/j.molbiopara.2005.08.018, PMID: 16202458
43. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ. 2002. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 79:539–546. doi: 10.1006/geno. 2002.6729, PMID: 11944986
44. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2010. U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Maryland: Bethesda.
45. Norris KC, Agodoa LY. 2002. Race and kidney disease: the scope of the problem. Journal of the National Medical Association 94:1S–6S. PMID: 12152909
46. Picozzi K, Fèvre EM, Odiit M, Carrington M, Eisler MC, Maudlin I, Welburn SC. 2005. Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ 331:1238–1241. doi: 10.1136/bmj.331.7527.1238, PMID: 16308383
47. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, Weatherall DJ, Hay SI. 2010. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nature Communications 1:104. doi: 10.1038/ncomms1104, PMID: 21045822
48. Pinto JC, Oliveira S, Teixeira S, Martins D, Fehn AM, Aço T, Gayà-Vidal M, Rocha J. 2016. Food and pathogen adaptations in the Angolan Namib desert: tracing the spread of lactase persistence and human african trypanosomiasis resistance into southwestern Africa. American Journal of Physical Anthropology 161:436–447. doi: 10.1002/ajpa.23042, PMID: 27402285
49. Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homblé F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. 2005. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309:469–472. doi: 10.1126/science.1114566, PMID: 16020735
50. Radwanska M, Chamekh M, Vanhamme L, Claes F, Magez S, Magnus E, de Baetselier P, Büscher P, Pays E. 2002. The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. The American Journal of Tropical Medicine and Hygiene 67:684–690. doi: 10.4269/ajtmh.2002.67. 684, PMID: 12518862
51. Samanovic M, Molina-Portela MP, Chessler AD, Burleigh BA, Raper J. 2009. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates leishmania infection. PLoS Pathogens 5:e1000276. doi: 10. 1371/journal.ppat.1000276, PMID: 19165337
52. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. 2005. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 29:256–269. doi: 10.1016/j.cyto. 2004.11.003, PMID: 15749026
53. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fèvre EM, Courtin F, Mattioli RC, Jannin JG. 2010. The Atlas of human african trypanosomiasis: a contribution to global mapping of neglected tropical diseases. International Journal of Health Geographics 9:57. doi: 10.1186/1476-072X-9-57, PMID: 21040555
54. Steverding D. 2008. The history of african trypanosomiasis. Parasites & Vectors 1:3. doi: 10.1186/1756-3305-1-3, PMID: 18275594
55. Tait A, Barry JD, Wink R, Sanderson A, Crowe JS. 1985. Enzyme variation in T. brucei ssp. II. evidence for T. b. Rhodesiense being a set of variants of T. b. brucei. Parasitology 90:89–100. doi: 10.1017/S0031182000049040, PMID: 3856830
56. Taylor SM, Parobek CM, Fairhurst RM. 2012. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. The Lancet Infectious Diseases 12:457–468. doi: 10.1016/S1473-3099(12) 70055-5, PMID: 22445352
57. Taylor HE, Khatua AK, Popik W. 2014. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. Journal of Virology 88:592–603. doi: 10.1128/JVI.02828-13, PMID: 24173214
58. Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J. 2014. Evolution of the primate trypanolytic factor APOL1. PNAS 111:E2130–E2139. doi: 10.1073/pnas.1400699111, PMID: 24808134
59. Thomson R, Finkelstein A. 2015. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. PNAS 112:2894–2899. doi: 10.1073/pnas.1421953112, PMID: 25730870
60. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo JB, Awomoyi AA, Bodo JM, Doumbo O, Ibrahim M, Juma AT, Kotze MJ, Lema G, Moore JH, Mortensen H, Nyambo TB, Omar SA, Powell K, Pretorius GS, et al. 2009. The genetic structure and history of africans and african Americans. Science 324: 1035–1044. doi: 10.1126/science.1172257, PMID: 19407144
61. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K. 2010. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Human Genetics 128:345–350. doi: 10.1007/s00439-010-0861-0, PMID: 20635188
62. Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homblé F, Grélard A, Zhendre V, Nolan DP, Lins L, Crowet JM, Pays A, Felu C, Poelvoorde P, Vanhollebeke B, Moestrup SK, Lyngsø J, Pedersen JS, Mottram JC, Dufourc EJ, et al. 2013. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 501: 430–434. doi: 10.1038/nature12516, PMID: 23965626
63. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, Pays E. 2003. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422:83–87. doi: 10.1038/nature01461, PMID: 12621437
64. Vanwalleghem G, Fontaine F, Lecordier L, Tebabi P, Klewe K, Nolan DP, Yamaryo-Botté Y, Botté C, Kremer A, Burkard GS, Rassow J, Roditi I, Pérez-Morga D, Pays E. 2015. Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1. Nature Communications 6:8078. doi: 10.1038/ncomms9078, PMID: 26307671
65. Weir W, Capewell P, Foth B, Clucas C, Pountain A, Steketee P, Veitch N, Koffi M, De Meeṷs T, Kaboré J, Camara M, Cooper A, Tait A, Jamonneau V, Bucheton B, Berriman M, MacLeod A. 2016. Population genomics reveals the origin and asexual evolution of human infective trypanosomes. eLife 5:e11473–14. doi: 10.7554/eLife. 11473, PMID: 26809473
66. Wolfe ND, Dunavan CP, Diamond J. 2007. Origins of Major human infectious diseases. Nature 447:279–283. doi: 10.1038/nature05775, PMID: 17507975
67. World Health Organization. 2015. Global Health Observatory Data Repository: Number of new reported cases of human African trypanosomiasis (1990-2015). http://apps.who.int/ghodata/
68. Xong HV, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, Pays A, Van Meirvenne N, Hamers R, De Baetselier P, Pays E. 1998. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 95:839–846. doi: 10.1016/S0092-8674(00)81706-7, PMID: 9865701